HKSE - Delayed Quote HKD

Innovent Biologics, Inc. (1801.HK)

79.750 -1.850 (-2.27%)

At close: October 30 at 4:08:06 PM GMT+8

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Altruist Biologics' Integrated CMC Platform Supports NMPA Acceptance of NDA for Localized Manufacturing of Multinational Client's Biologic

PR Newswire 1d ago

1801.HK
-2.27%
1801
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

PR Newswire 4d ago

1801.HK
-2.27%
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

PR Newswire 5d ago

1801.HK
-2.27%
TAK
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

PR Newswire 5d ago

1801.HK
-2.27%
Phase 3 Cancer Trial Win Could Be A Game Changer For Innovent Biologics Stock

Simply Wall St. 6d ago

1801.HK
-2.27%
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

PR Newswire 7d ago

1801.HK
-2.27%
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

PR Newswire 7d ago

1801.HK
-2.27%
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

PR Newswire 22d ago

1801.HK
-2.27%
Innovent Biologics (SEHK:1801) Stock Still Looks Below Fair Value As Shares Rose 153%

Simply Wall St. 1mo ago

1801.HK
-2.27%
$2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma$

2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma

PR Newswire 1mo ago

1801.HK
-2.27%
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

PR Newswire 1mo ago

1801.HK
-2.27%
TAK
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting

PR Newswire 1mo ago

1801.HK
-2.27%

Performance Overview

Return	1801.HK	HANG SENG INDEX (^HSI)
YTD	+4.59%	-9.11%
1-Year	-1.18%	-11.37%
3-Year	+69.50%	+33.83%

U.S. markets closed

Innovent Biologics, Inc. (1801.HK)

Altruist Biologics' Integrated CMC Platform Supports NMPA Acceptance of NDA for Localized Manufacturing of Multinational Client's Biologic

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

Phase 3 Cancer Trial Win Could Be A Game Changer For Innovent Biologics Stock

2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

Innovent Biologics (SEHK:1801) Stock Still Looks Below Fair Value As Shares Rose 153%

2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting